RxDoctor Payments Data

Victoria Brothers, PA

Physician Assistant · Fort Worth, TXNPI 1962143313

Payments from drug & device makers

$6,462in general payments, 2019–2025

Across 308 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$997
  • Regeneron Healthcare Solutions, Inc.$755
  • Mylan Specialty L.p.$448
  • Boehringer Ingelheim$397
  • Sanofi$325
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,462 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$41,657
Medicare patients
238
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter330$260,978
OfevNintedanib Esylate15$185,172
Breztri AerosphereBudesonide/Glycopyr/Formoterol154$120,175
Breo ElliptaFluticasone/Vilanterol116$60,658
SymbicortBudesonide/Formoterol Fumarate112$38,145
Spiriva RespimatTiotropium Bromide50$30,217
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$23,131
EliquisApixaban14$7,743
Albuterol Sulfate HfaAlbuterol Sulfate294$7,336
Spiriva HandihalerTiotropium Bromide13$6,397
Fluticasone-SalmeterolFluticasone Propion/Salmeterol46$6,133
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$4,356
Varenicline Tartrate13$4,240
Arnuity ElliptaFluticasone Furoate16$3,778
Wixela InhubFluticasone Propion/Salmeterol27$2,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,265$348,545497 claims
Boehringer IngelheimOfev, Spiriva Respimat$397$215,39065 claims
AstraZenecaBreztri Aerosphere, Symbicort$997$158,320266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →